15 results about "Faecalibacterium prausnitzii" patented technology

This invention discloses a dietary factor and its combination that targets gut microbiota to improve exercise performance, belonging to the fields of microbial technology and pharmaceutical technology. Experimental verification shows that the dietary factor combination can increase the abundance of *Eubacterium rectale*, *Faecalibacterium prausnitzii*, and *Veillonella* species; a combination of galactooligosaccharides, burdock seed, matsutake polysaccharide, and galactooligosaccharides; a combination of burdock seed and matsutake polysaccharide; and a combination of burdock seed and galactooligosaccharides can increase the concentration of fatty acid amides; curcumin and the combination of curcumin, burdock seed, and galactooligosaccharides show the best effect in promoting the content of fecal microbiota after acetic acid fermentation; and a mixed combination of *Bifidobacterium adolescentis* CCFM1066, *Bifidobacterium longum* CCFM1306, curcumin, inulin, burdock seed, matsutake polysaccharide, and galactooligosaccharides shows the most significant effect in increasing the time spent swimming at exhaustion under load in exercised mice.

The application provides application of intestinal flora as a marker in preparation of a product for evaluating treatment effect of inflammatory bowel disease. The feasibility of using a microbial spectrum to predict the curative effect of drug treatment on patients with inflammatory bowel disease is achieved, and the achievement can accurately identify patients who need to optimize the treatment scheme in the early stage of the disease, thereby significantly improving the prognosis of the patients. Meanwhile, a construction method of an intestinal flora biomarker prediction model is provided, and through the combination of Faecalibacterium prausnitzii, Blautia massiliensis and Phascolarctobacterium faecium, the precise prediction of the invalid condition of drug treatment is realized, which highlights the potential of the new tool for early identification of patients who may need to optimize the treatment.

The application discloses an adult depression intestinal microorganism marker and application thereof, and belongs to the field of biological medicine. The microorganism marker comprises one or more of the following: Clostridium aldrichii, Coprococcus comes, Klebsiella pneumoniae, Bifidobacterium adolescentis, Bacteroides vulgatus, Eubacterium eligens and Faecalibacterium prausnitzii. The application provides a product (such as a kit) comprising detection reagents for detecting the relative abundance of the microorganism marker. The product provided by the application has good feasibility and accuracy, and can effectively evaluate the risk of whether an adult has depression, thereby providing a new tool for clinical diagnosis.

The application discloses an intestinal flora marker related to obstructive sleep apnea with obesity, a product and application thereof, and the intestinal flora marker combination is a marker combination composed of Streptococcus thermophilus, Faecalibacterium prausnitzii, Dorea longicatena and Bacteroides finegoldii. The application of a reagent for detecting the intestinal flora marker combination in preparation of a product for diagnosing obstructive sleep apnea with obesity is characterized in that the reagent comprises cetyltrimethylammonium bromide. The application provides a new idea and approach for diagnosis and treatment of obstructive sleep apnea with obesity.

The present invention relates to an intestinal microorganism-based composition for enhancing the efficacy of vaccinations, in particular, the persistence of antibody reactions and booster effects. The present inventors have found that specific intestinal microorganisms are significantly abundant in individuals having a long antibody half-life following vaccination with an mRNA vaccine or an adenovirus vector vaccine, or exhibiting a high immune response upon booster vaccination. Specifically, it was found that a specific microbial community including Faecalibacterium prausnitzii is associated with antibody persistence and booster response enhancement following mRNA vaccination, and Escherichia coli is associated with antibody persistence following adenovirus vector vaccination.

The invention discloses a chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation as well as a preparation method and application of the chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation. According to the nano preparation, outer membrane vesicles derived from fecal bacillus rodent are taken as a delivery carrier, and an anti-PD-L1 antibody is stably coupled to the surfaces of the vesicles under the chemical cross-linking action of DSPE-PEG-NHS, so that the composite nano preparation MVs / alpha-PD-L1 is formed; in-vitro experiments show that the composite nano preparation can significantly inhibit the activity of breast cancer cells and induce apoptosis of the breast cancer cells; in a 4T1 in-situ breast cancer mouse model, tumor growth can be effectively inhibited, a tumor immune microenvironment can be remodeled, the biological safety is good, and a safe and effective novel delivery system is provided for targeted immunotherapy of breast cancer.

The invention discloses clostridium pralaense for improving the intestinal barrier function of a mouse with chronic kidney disease and application of the clostridium pralaense, and belongs to the technical field of microorganisms and the technical field of medicines. The clostridium prausnitzii CCFM1204 provided by the invention has beneficial effects in delaying the renal failure process, can significantly improve kidney pathological characteristics of mice with adenine-induced chronic nephropathy, reduce the serum urea nitrogen level, reduce the collagen volume fraction of kidney tissues, improve the intestinal barrier function, and can be used for preventing and treating the chronic nephropathy of the mice with adenine-induced chronic nephropathy, so that the clostridium prausnitzii CCFM1204 can be used for preventing and treating the chronic nephropathy of the mice with adenine-induced chronic nephropathy of the mice with adenine-induced chronic nephropathy. The serum LPS level and the expression quantity of proinflammatory factors in the colon tissue are reduced, and the expression quantity of tight junction proteins in the colon tissue is improved. The clostridium praeparatum CCFM1204 provided by the invention has a wide application prospect in preparation of drugs for relieving or improving intestinal barrier dysfunction related to chronic kidney diseases.

A use of gut microbiota or a metabolite thereof and / or an antibody or a derivative thereof in preparation of immunotherapeutic drugs for colorectal cancer. The gut microbiota comprises at least one of Alistipes shahii, Butyricimonas virosa, Desulfovibrio piger, Actinomyces humiferus, Odoribacter splanchnicus, Faecalibacterium prausnitzii, Phocaeicola plebeius, Eubacterium rectale, Oscillospiraceae bacterium, and Alistipes onderdonkii. The metabolite of the gut microbiota comprises at least one of O-phosphorylethanolamine, 5,6-dihydroxyindole-2-carboxylic acid, phosphatidylcholine (O-16:0_20:4), and 4-acetamidobutyric acid. The antibody comprises an IL-17A signaling pathway monoclonal antibody and / or a colorectal cancer-targeted monoclonal antibody.

The invention discloses a bifidobacterium longum subsp. Longum for relieving an intestinal flatulence symptom by improving the abundance of butyric acid producing bacteria in an intestinal tract and application of the bifidobacterium longum subsp. Longum, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides an application of bifidobacterium longum subsp. Longum CCFM1319 in relieving intestinal flatulence. The application is specifically characterized in that generation of fermentation byproduct gas can be reduced, growth advantages are obtained in intestinal tracts, and abundance of butyric acid producing bacteria is improved; the gastrointestinal symptom score of people with intestinal flatulence is obviously improved; the scale score of the flatulence-related symptoms is obviously improved; and the absolute abundance of butyric acid producing bacteria (clostridium praeparatum) in intestinal tracts of people with intestinal flatulence is obviously improved. The bifidobacterium longum subsp. Longum CCFM1319 and the effective components thereof have good safety, have treatment application and can be used for developing probiotic products. Therefore, the bifidobacterium longum subsp. Longum CCFM1319 has a huge application prospect in preparation of medicines for preventing and / or treating intestinal flatulence.

Aspects of the disclosure encompass compositions and therapeutic methods for treating subjects having gastrointestinal disorders. The compositions provided herein can be formulated as live biotherapeutic products (LBP), fecal microbiota transplant (FMT) products and FMT enrichment compositions, probiotics and food products, and comprise one or more of the bacterial species Faecalibacterium prausnitzii, Bifidobacterium adolescentis, Bifidobacterium longum, Eubacterium rectale or combinations thereof. In certain aspects, an individual is determined to be a suitable recipient for these therapies based on classification of the taxa profile of their microbiome.

Provided is at least one agent selected from the group consisting of (a) a gut microbiota or a metabolite thereof and (b) an antibody or a derivative thereof for use in immunotherapy of colorectal cancer. The gut microbiota includes at least one selected from the group consisting of Alistipes shahii, Butyricimonas virosa, Desulfovibrio piger, Alistipes putredinis, Odoribacter splanchnicus, Faecalibacterium prausnitzii, Phocaeicola plebeius, Eubacterium rectale, Oscillospiraceae bacterium, and Alistipes onderdonkii. The gut microbiota or the metabolite thereof and / or the antibody or the derivative thereof in this application can enhance the anti-tumor effect of immunotherapy, and demonstrate the functions of regulating the immune microenvironment and improving sensitivity to tumor immunotherapy.

To provide a method for evaluating dementia, and a composition for preventing or treating a decline in brain function, or for maintaining or improving brain function. [Solution] The gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease were compared. As a result, microorganisms belonging to the genus Faecalibacterium were selected as gut microbiota associated with cognitive function. Furthermore, it was revealed that Faecalibacterium prausnitzii, which possesses specific DNA, has an improving effect on cognitive decline such as learning and memory impairment.

The invention discloses application of fecal bacillus przewalskii FPS03 in preparation of drugs for preventing or treating inflammatory diseases, and belongs to the technical field of microorganisms. According to the application of the faecalis przewalskii FPS03 in preparing the medicine for preventing or treating the inflammatory diseases, disclosed by the invention, the faecalis przewalskii FPS03 can be used for inhibiting neutrophil and macrophage from gathering towards the inflammation part of the tail fin of zebra fish in an in-vivo inflammation model; the fecal bacillus przewalskii FPS03 can be used for inhibiting the increase of the content of LPS-induced inflammatory factors such as IL-1beta, IL-6 and TNF-alpha (Tumor Necrosis Factor-alpha); theoretical reference and guidance basis are provided for developing medicines for preventing or treating inflammatory diseases by utilizing the fecal bacillus przewalskii FPS03.

A pharmaceutical composition effective for the prevention or treatment of atopic disease is disclosed. The pharmaceutical composition contains a Faecalibacterium prausnitzii EB-FPDK11 strain or a culture or dried product thereof. While traditional probiotics generally have an insignificant therapeutic effect for atopic disease, the pharmaceutical composition of the present invention exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.

The invention belongs to the technical field of biological medicine and neural immune regulation and control, and discloses a composition based on Faecalibacterium prausnitzii and application of the composition in stroke, post-stroke cognitive impairment (PSCI) and vascular dementia (VaD), and the composition comprises the Faecalibacterium prausnitzii, namely Fp or a derivative of the Faecalibacterium prausnitzii. The invention provides and verifies the application of the Faecalibacterium prausnitzii and the derivative thereof in the whole stroke course (acute stage, PSCI, VaD and cerebral small vascular disease), innovatively reveals a gut-thymus-train axis action mechanism, forms a clinical-animal-mechanism-preparation-diagnosis complete chain, fills up the blank in the prior art, and has remarkable novelty, creativity and industrial application value.